

Message

From: Miquelon, Wade [wade.miquelon@walgreens.com]
Sent: 8/15/2013 5:44:43 PM
To: Garza, Debbie [debbie.garza@walgreens.com]
Subject: Final National Roll Out Plan

She's met w almost every governor, sebelius, etc many times and can save Medicare alone 85b over 10 years. I'm not worried about them or labs.... I'm worried about us :(

W

On Aug 15, 2013, at 5:06 PM, "Garza, Debbie" <debbie.garza@walgreens.com> wrote:

Thanks Wade. Those stats and specifics you mentioned about where already used in govt (ie, military, etc) will really be helpful as I am sure there will be push back by Congressional offices and state legislators as pushed by Quest and Lab Corp. Funny thing, the NACDS vp of policy I have worked with for years very recently took over the head of policy and govt affairs for the labs trade association :)

Good to see you today.

-Debbie

On Aug 15, 2013, at 4:09 PM, "Miquelon, Wade" <wade.miquelon@walgreens.com> wrote:

FYI

Begin forwarded message:

From: Elizabeth Holmes <eholmes@theranos.com>
Date: August 7, 2013, 3:33:19 PM CDT
To: "Miquelon, Wade" <wade.miquelon@walgreens.com>
Subject: FW: Final National Roll Out Plan

Dear Wade,

I hope this email finds you great.

We have cemented what we believe to be the most effective rollout strategy for realizing broad national scale as fast as possible. This rollout schedule allows us to be as efficient with our operational infrastructure as possible while achieving scale in the shortest amount of time.

The geographical roll out plan was developed to maximize speed of deployment to the largest metropolitan areas, to Medicare patients, and to chronically ill populations (who currently do >13 tests/person/year). We are attaching a document that shows our rollout recommendation to locations across different regions, starting now and running through the end of 2014. This deployment plan achieves national distribution of Theranos services at Walgreens by the end of 2014.

As part of this plan, we would like to launch in New York City with Walgreens by early Q1 of 2014. We would work toward opening a new lab facility in New York City by late September, immediately after our launch in Palo Alto and Phoenix. We think we would be ready for New York City launch by January, with

possible 1+ showcase stores launched in 2013 and announcements with Mayor Bloomberg this year (we have had several meetings with him on this and have also started working with the NYC Health Commission).

There is a very significant amount of work the Walgreens team will also have to do for this, including establishing a more robust and formal technician training program and preparing space for Theranos services in New York City. In line with this, the five core operational focal areas we've had the opportunity to discuss and have highlighted here below are instrumental to successfully executing our plan together.

1. The first core focal area is training. Thorough and ongoing training of our Walgreens technicians is key to our program success. After initial certification, we need to make sure our technicians receive ongoing refreshment and skill maintenance courses. Our 'train the trainer' program must ensure complete certification of trainers before those trainers begin training new technicians. We also want to be sure to include the development of 'mentors' who can provide oversight to technicians across various stores. Inherent to this training is also training on patient interaction and experience.

2. The second core focal area is the space. We would like to make an argument that Walgreens provide us either with space currently used for the photo lab at Duane Read stores, or a similar space around 150-200 ft2 for a dedicated room and bathroom for lab services. We believe this investment in infrastructure will pay off very well for Walgreens given the tremendous market opportunity. As a reference, the above recommended space footprint in New York City is similar in size or smaller than the space currently allocated to photo services in Duane Read stores in New York City.

3. Our next area of focus is the ongoing investment Theranos is making and needs to make in scaling up to realize this plan. Per our discussions, in order to roll out faster nationally, Theranos would require some of the existing pre-purchase payments from Walgreens sooner than currently anticipated in our contract. Our current contract anticipates the next pre-payment of \$25M upon successful completion of pilot, and then an additional pre-payment of \$50M at the beginning of our national launch, which we previously anticipated to be around end of this year (within 30 days or so of our formal pilot success). As per our conversation, we split those outstanding pre-purchase commitments into three sequential payments starting on September 1st. In order for us to accelerate, proceed now with, and scale the national launch, we would ask for the 1st of those pre-payments of \$35M on September 1, 2013 and the 2 subsequent pre-payments of \$20m each on November 1, 2013 and December 15, 2013.

4. The fourth core focal area is the operational infrastructure. The logistics of construction for the space, supply chain security, and distribution will require management to ensure rapid scalability.

5. Finally, our fifth core focal area is marketing. Direct to consumer marketing will be critical to driving our demand and foot traffic. We have been investing heavily in the consumer content and the media partnership with Walgreens to reach consumers and drive consumers to ask their physicians to send them to Theranos will be a core tenet of our success. Fully leveraging Walgreens media and consumer reach in this context will benefit our rollout success greatly.

We look forward to discussing the above and the associated work streams with you (in as much detail as you'd like) at your convenience.

It will be wonderful to have you here next week.

With my best regards,

Elizabeth

=====

PRIVILEGED AND CONFIDENTIAL COMMUNICATION

IMPORTANT - This electronic transmission, and any files transmitted with it are confidential and/or legally privileged information. This information is intended solely for the use of the individual or entity to which they are addressed. Any disclosure, retransmission, reproduction, dissemination or other use of the contents of this information by persons or entities other than the intended recipient is strictly prohibited. If you have received this email in error, please contact us immediately and delete all copies. Please note that any views or opinions presented in this email are solely those of the author and do not necessarily represent those of Theranos, Inc. Finally, before opening or using attachments the recipient should check this email and any attachments for the presence of viruses. Theranos, Inc. accepts no liability for any damage caused by any virus transmitted by this email. Our sole responsibility is limited to resupplying any affected attachments.

Theranos, Inc., 1601 S. California Avenue, Palo Alto, CA, 94304

650-838-9292 www.theranos.com

=====

<Retail Strategy Plan_vF.pptx>